Autopsy report · NCT01078974

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

“Safety concerns (IgM Flare)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 years 10 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Steven P. Treon, MD, PhD

Sponsor type

University, hospital or other

Conditions

Waldenstrom's Macroglobulinemia

Interventions

pomalidomide; dexamethasone; rituximab

Participants

7

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.